Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970833417> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2970833417 endingPage "4560" @default.
- W2970833417 startingPage "4560" @default.
- W2970833417 abstract "4560 Background: Oxaliplatin (OX), gemcitabine (GEM) and capecitabine (CAP) are all active agents against various gastrointestinal and other malignancies and have different mechanisms of action and toxicity profiles. This Phase I study aims to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) associated with this triplet regimen. Methods: The modified Fibonacchi 3/cohort dose escalation schema was used to determine the MTD and DLT of OX, GEM and CAP. Oxalipaltin [85–100 mg/m 2 ] IV over 2 hours and gemcitabine [800–1,000 mg/m 2 ] were given at a constant rate infusion of 10 mg/m 2 /min on days 1 & 15, while CAP [600–800 mg/m 2 ] was given PO BID on days 1–7 and 15–21. 1 cycle = 28 days. Pharmacogenomic correlates including ERCC2, GSTP1, TYMS, TS del and TSER G>C were also obtained. A structured neurological toxicity assessment and questionnaire was also performed. Once MTD was established, additional patients were treated at the MTD and pharmacokinetic studies were performed on these additional patients. Results: 30 patients (M:F 2:1; 23% non-caucasian) with median age of 62 (range: 38–78) and PS of 0–1 were enrolled from 3/05 to 8/06. All patients had advanced GI malignancies (19 pancreatic, 6 biliary, 2 duodenal, 1 gastric, 1 esophageal, 1 GI unknown primary). Dose levels, # patients, DLT and best responses are tabulated below. Conclusions: The MTD of this triplet regimen is OX at 100 mg/m 2 , GEM at 800 mg/m 2 days 1 & 15 with CAP at 800 mg/m 2 PO BID days 1–7, 15–21. DLTs for this regimen include grade 3 fatigue and dyspnea as well as Grade 4 thrombocytopenia. CR is achieved in 2 patients (cholangiocarcinoma and pancreatic), while a patient with a GI unknown primary achieved PR. Several patients with pancreatic cancer achieved prolonged SD. An exploration of any association of toxicities and response with pharmacogenomic correlates is ongoing. A Phase II study in patients with pancreaticobiliary cancers is planned. This study is supported by Sanofi-Aventis Pharmaceuticals. [Table: see text] [Table: see text]" @default.
- W2970833417 created "2019-09-05" @default.
- W2970833417 creator A5008067066 @default.
- W2970833417 creator A5011034688 @default.
- W2970833417 creator A5023299141 @default.
- W2970833417 creator A5030408716 @default.
- W2970833417 creator A5032863864 @default.
- W2970833417 creator A5034354367 @default.
- W2970833417 creator A5040886856 @default.
- W2970833417 creator A5084886650 @default.
- W2970833417 date "2007-06-20" @default.
- W2970833417 modified "2023-09-27" @default.
- W2970833417 title "Biweekly oxaliplatin with gemcitabine and capecitabine in advanced gastrointestinal malignancies: A phase I study" @default.
- W2970833417 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.4560" @default.
- W2970833417 hasPublicationYear "2007" @default.
- W2970833417 type Work @default.
- W2970833417 sameAs 2970833417 @default.
- W2970833417 citedByCount "0" @default.
- W2970833417 crossrefType "journal-article" @default.
- W2970833417 hasAuthorship W2970833417A5008067066 @default.
- W2970833417 hasAuthorship W2970833417A5011034688 @default.
- W2970833417 hasAuthorship W2970833417A5023299141 @default.
- W2970833417 hasAuthorship W2970833417A5030408716 @default.
- W2970833417 hasAuthorship W2970833417A5032863864 @default.
- W2970833417 hasAuthorship W2970833417A5034354367 @default.
- W2970833417 hasAuthorship W2970833417A5040886856 @default.
- W2970833417 hasAuthorship W2970833417A5084886650 @default.
- W2970833417 hasConcept C121608353 @default.
- W2970833417 hasConcept C126322002 @default.
- W2970833417 hasConcept C2777063308 @default.
- W2970833417 hasConcept C2777909004 @default.
- W2970833417 hasConcept C2778496288 @default.
- W2970833417 hasConcept C2780258809 @default.
- W2970833417 hasConcept C2780259306 @default.
- W2970833417 hasConcept C2780580376 @default.
- W2970833417 hasConcept C2780962732 @default.
- W2970833417 hasConcept C2781413609 @default.
- W2970833417 hasConcept C29730261 @default.
- W2970833417 hasConcept C526805850 @default.
- W2970833417 hasConcept C71924100 @default.
- W2970833417 hasConcept C90924648 @default.
- W2970833417 hasConceptScore W2970833417C121608353 @default.
- W2970833417 hasConceptScore W2970833417C126322002 @default.
- W2970833417 hasConceptScore W2970833417C2777063308 @default.
- W2970833417 hasConceptScore W2970833417C2777909004 @default.
- W2970833417 hasConceptScore W2970833417C2778496288 @default.
- W2970833417 hasConceptScore W2970833417C2780258809 @default.
- W2970833417 hasConceptScore W2970833417C2780259306 @default.
- W2970833417 hasConceptScore W2970833417C2780580376 @default.
- W2970833417 hasConceptScore W2970833417C2780962732 @default.
- W2970833417 hasConceptScore W2970833417C2781413609 @default.
- W2970833417 hasConceptScore W2970833417C29730261 @default.
- W2970833417 hasConceptScore W2970833417C526805850 @default.
- W2970833417 hasConceptScore W2970833417C71924100 @default.
- W2970833417 hasConceptScore W2970833417C90924648 @default.
- W2970833417 hasIssue "18_suppl" @default.
- W2970833417 hasLocation W29708334171 @default.
- W2970833417 hasOpenAccess W2970833417 @default.
- W2970833417 hasPrimaryLocation W29708334171 @default.
- W2970833417 hasRelatedWork W1970283121 @default.
- W2970833417 hasRelatedWork W1990994894 @default.
- W2970833417 hasRelatedWork W2008532487 @default.
- W2970833417 hasRelatedWork W2067068996 @default.
- W2970833417 hasRelatedWork W2069840290 @default.
- W2970833417 hasRelatedWork W2146230542 @default.
- W2970833417 hasRelatedWork W2358087495 @default.
- W2970833417 hasRelatedWork W2374642528 @default.
- W2970833417 hasRelatedWork W244746785 @default.
- W2970833417 hasRelatedWork W2589169337 @default.
- W2970833417 hasVolume "25" @default.
- W2970833417 isParatext "false" @default.
- W2970833417 isRetracted "false" @default.
- W2970833417 magId "2970833417" @default.
- W2970833417 workType "article" @default.